Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways

References

• Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Alimentary Pharmacology & Therapeutics. 2011;34(3):274–285.21623852
   PubMed Web of Science ®Google Scholar
• Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389–398. doi:10.1016/S2468-1253(19)30039-130902670
   PubMed Web of Science ®Google Scholar
• National Workshop on Fatty L, Alcoholic Liver Disease CSoHCMA, Fatty Liver Expert Committee CMDA. [Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology. 2018;26(3):195–203.29804393
   PubMedGoogle Scholar
• Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. Journal of Gastroenterology and Hepatology. 2016;31(5):936–944.26667191
   PubMedGoogle Scholar
• Younossi ZM. Non-alcoholic fatty liver disease ——2013; A global public health perspective. Journal of hepatology. 2019;70(3):531–544.30414863
   PubMed Web of Science ®Google Scholar
• Chen Z, Jain A, Liu H, Zhao Z, Cheng K. Targeted drug delivery to hepatic stellate cells for the treatment of liver fibrosis. J Pharmacol Exp Ther. 2019;370(3):695–702. doi:10.1124/jpet.118.25615630886124
   PubMed Web of Science ®Google Scholar
• Negrin KA, Roth Flach RJ, DiStefano MT, et al. IL-1 Signaling in Obesity-Induced Hepatic Lipogenesis and Steatosis. PLOS ONE. 2014;9(9):e107265.25216251
   PubMed Web of Science ®Google Scholar
• Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409–1439. doi:10.1152/physrev.00034.200617928588
   PubMed Web of Science ®Google Scholar
• Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17(6):819–837. doi:10.1016/j.cmet.2013.04.00823684623
   PubMed Web of Science ®Google Scholar
• Pugazhenthi U, Velmurugan K, Tran A, Mahaffey G, Pugazhenthi S. Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients. Diabetologia. 2010;53(11):2357–2368. doi:10.1007/s00125-010-1849-y20635178
   PubMed Web of Science ®Google Scholar
• He Q, Sha S, Sun L, Zhang J, Dong M. GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway. Biochemical and Biophysical Research Communications. 2016;476(4):196–203.27208776
   PubMed Web of Science ®Google Scholar
• Bernsmeier C, Meyer-Gerspach AC, Blaser LS, et al. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease. PLoS One. 2014;9(1):e87488. doi:10.1371/journal.pone.008748824489924
   PubMed Web of Science ®Google Scholar
• Gupta NA, Mells J, Dunham RM, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology. 2010;51(5):1584–1592. doi:10.1002/hep.2356920225248
   PubMed Web of Science ®Google Scholar
• Svegliati-Baroni G, Saccomanno S, Rychlicki C, et al. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. Liver Int. 2011;31(9):1285–1297. doi:10.1111/liv.2011.31.issue-921745271
   PubMed Web of Science ®Google Scholar
• Tong J, D’Alessio D. Give the receptor a brake: slowing gastric emptying by GLP-1. Diabetes. 2014;63(2):407–409. doi:10.2337/db13-176424464721
   PubMed Web of Science ®Google Scholar
• Chen W-R, Shen X-Q, Zhang Y, et al. Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction. Endocrine. 2016;52(3):516–526.26573925
   PubMed Web of Science ®Google Scholar
• Liang Y, Li Z, Liang S, et al. Hepatic adenylate cyclase 3 is upregulated by Liraglutide and subsequently plays a protective role in insulin resistance and obesity. Nutr Diabetes. 2016;6:e191.26807509
   PubMed Web of Science ®Google Scholar
• Li Z, Yang P, Liang Y, et al. Effects of liraglutide on lipolysis and the AC3/PKA/HSL pathway. Diabetes, metabolic syndrome and obesity: Targets and Therapy. 2019;12:1697–1703.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357. doi:10.1002/hep.2936728714183
   PubMed Web of Science ®Google Scholar
• Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. diabetes care. 2018;41(2):372–382. doi:10.2337/dc17-190229358469
   PubMed Web of Science ®Google Scholar
• Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2018;53(3):362–376. doi:10.1007/s00535-017-1415-129247356
   PubMed Web of Science ®Google Scholar
• Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000;43(4):527–550. doi:10.1021/jm990554g10691680
   PubMed Web of Science ®Google Scholar
• Brown JD, Plutzky J. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets. Circulation. 2007;115(4):518–533. doi:10.1161/CIRCULATIONAHA.104.47567317261671
   PubMed Web of Science ®Google Scholar
• Zhang Q, Xiao X, Zheng J, et al. Liraglutide protects cardiac function in diabetic rats through the PPARalpha pathway. Biosci Rep. 2018;38.
   Web of Science ®Google Scholar
• Decara J, Arrabal S, Beiroa D, et al. Antiobesity efficacy of GLP-1 receptor agonist liraglutide is associated with peripheral tissue-specific modulation of lipid metabolic regulators. Biofactors. 2016;42(6):600–611. doi:10.1002/biof.v42.627213962
   PubMed Web of Science ®Google Scholar
• Nagarajan P, Mahesh Kumar MJ, Venkatesan R, Majundar SS, Juyal RC. Genetically modified mouse models for the study of nonalcoholic fatty liver disease. World J Gastroenterol. 2012;18(11):1141–1153. doi:10.3748/wjg.v18.i11.114122468076
   PubMed Web of Science ®Google Scholar
• Arisqueta L, Navarro-Imaz H, Labiano I, Rueda Y, Fresnedo O. High-fat diet overfeeding promotes nondetrimental liver steatosis in female mice. Am J Physiol Gastrointest Liver Physiol. 2018;315(5):G772–G780. doi:10.1152/ajpgi.00022.201830095299
   PubMed Web of Science ®Google Scholar
• Xu H, Zhou Y, Liu Y, et al. Metformin improves hepatic IRS2/PI3K/Akt signaling in insulin-resistant rats of NASH and cirrhosis. J Endocrinol. 2016;229(2):133–144. doi:10.1530/JOE-15-040926941037
   PubMed Web of Science ®Google Scholar
• Tolbol KS, Kristiansen MN, Hansen HH, et al. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World J Gastroenterol. 2018;24(2):179–194. doi:10.3748/wjg.v24.i2.17929375204
   PubMed Web of Science ®Google Scholar
• Yang P, Liang Y, Luo Y, et al. Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway. Diabetes Metab Syndr Obes. 2019;12:1013–1021. doi:10.2147/DMSO.S20686731308717
   PubMed Web of Science ®Google Scholar
• Ipsen DH, Rolin B, Rakipovski G, et al. Liraglutide decreases hepatic inflammation and injury in advanced lean non-alcoholic steatohepatitis. Basic Clin Pharmacol Toxicol. 2018;123(6):704–713. doi:10.1111/bcpt.2018.123.issue-629953740
   PubMed Web of Science ®Google Scholar
• Zhu W, Feng PP, He K, Li SW, Gong JP. Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet. Biochem Biophys Res Commun. 2018;505(2):523–529. doi:10.1016/j.bbrc.2018.09.13430269815
   PubMed Web of Science ®Google Scholar
• Stienstra R, Joosten LAB, Koenen T, et al. The Inflammasome-Mediated Caspase-1 Activation Controls Adipocyte Differentiation and Insulin Sensitivity. Cell metabolism. 2010;12(6):593–605.21109192
   PubMed Web of Science ®Google Scholar
• Tan Q, Hu J, Yu X, et al. The Role of IL-1 Family Members and Kupffer Cells in Liver Regeneration. BioMed Research International. 2016;2016:6.
   Web of Science ®Google Scholar
• Patrick AL, Rullo J, Beaudin S, Liaw P, Fox-Robichaud AE. Hepatic leukocyte recruitment in response to time-limited expression of TNF-α and IL-1β. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2007;293(4):G663–G672.
   Google Scholar
• Jain A, Barve A, Zhao Z, et al. Targeted delivery of an siRNA/PNA hybrid nanocomplex reverses carbon tetrachloride-induced liver fibrosis. Adv Ther. 2019;2(8):1900046. doi:10.1002/adtp.v2.8
   Google Scholar
• Akash MSH, Rehman K, Liaqat A. Tumor Necrosis Factor-Alpha: Role in Development of Insulin Resistance and Pathogenesis of Type 2 Diabetes Mellitus. J Cell Biochem. 2018;119(1):105–110.28569437
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87–91.7678183
   PubMed Web of Science ®Google Scholar
• Tsiotra PC, Tsigos C, Raptis SA. TNFalpha and leptin inhibit basal and glucose-stimulated insulin secretion and gene transcription in the HIT-T15 pancreatic cells. Int J Obes Relat Metab Disord. 2001;25(7):1018–1026.11443501
   PubMed Web of Science ®Google Scholar
• Tak PP, Firestein GS. NF-κB: a key role in inflammatory diseases. The Journal of Clinical Investigation. 2001;107(1):7–11.11134171
   PubMed Web of Science ®Google Scholar
• Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes. 2010;59(4):1030–1037. doi:10.2337/db09-169420068138
   PubMed Web of Science ®Google Scholar
• Shiraki A, Oyama J, Komoda H, et al. The glucagon-like peptide 1 analog liraglutide reduces TNF-alpha-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis 2012;221(2):375–382.
   Google Scholar